Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health~* Willing to be followed for the duration of the study~* Willing to use acceptable methods of contraception~Exclusion Criteria:~* Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, may affect the ability of the volunteer to understand and cooperate with the study~* Liver disease (ALT greater than upper limit of normal \[ULN\])~* Kidney disease (serum creatinine greater than ULN)~* Hematologic disease (absolute neutrophil count of less than 1,500 cells/mm3; hemoglobin less than lower limit of normal, by sex; OR platelet count less than 140,000 mm3)~* Clinically significant neurologic, heart, lung, liver, rheumatologic, autoimmune, or kidney disease~* Participation in another investigational vaccine or drug trial within 30 days of study entry or while this study is ongoing~* Active drug or alcohol abuse causing medical, occupational, or family problems during the 12 months prior to study entry~* History of severe allergic reaction or anaphylaxis~* HIV-1 infected~* Hepatitis C virus infected~* Hepatitis B surface antigen positive~* Known immunodeficiency syndrome~* Use of corticosteroids or immunosuppressive drugs within 30 days prior to study entry. Participants who have used topical or nasal corticosteroids are not excluded.~* Live vaccine within 4 weeks prior to study entry~* Killed vaccine within 2 weeks prior to study entry~* Blood products within 6 months prior to study entry~* Absence of spleen~* Previously received an investigational malaria vaccine~* Received antimalarial prophylaxis during the 12 months prior to study entry~* Received chloroquine or other aminoquinolines within 12 weeks of study entry~* Prior malaria infection~* Known allergy to nickel~* Pre-existing autoimmune or antibody-mediated disease. More information about this criterion can be found in the protocol.~* Any medical, psychiatric, social, or occupational condition or other responsibility that, in the opinion of the investigator, would interfere with the study~* Other condition that, in the opinion of the investigator, would affect the volunteer's participation in the study~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): 3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm B.
- B (Type: EXPERIMENTAL): 3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm A.
- C (Type: EXPERIMENTAL): 3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm D after review of the results from Arms A and B.
- D (Type: EXPERIMENTAL): 3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm C after review of the results from Arms A and B.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete